Harvard University Stock Portfolio: 5 Latest Stock Picks

4. Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Harvard Management Company’s Stake Value: $5.85 million
Percentage of Harvard Management Company’s 13F Portfolio: 0.34%
Number of Hedge Fund Holders: 27

Pacific Biosciences of California, Inc. (NASDAQ:PACB) is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation.

On October 14, Cowen transferred coverage of Pacific Biosciences of California, Inc. (NASDAQ:PACB) to analyst Dan Brennan, who maintained a Market Perform rating and $30 price target on the stock.

Harvard Management Company held 229,144 Pacific Biosciences of California, Inc. (NASDAQ:PACB) shares by the end of the third quarter, worth $5.85 million, representing 0.34% of the firm’s portfolio. Out of the 867 hedge funds surveyed by Insider Monkey during the same time period, 27 held a stake in the company.

Among the hedge funds being tracked by Insider Monkey, Catherine Wood’s ARK Investment Management is a leading shareholder in Pacific Biosciences of California, Inc. (NASDAQ:PACB) with 22.7 million shares worth more than $580.5 million.

In its Q2 2021 investor letter, DEVON Equity Management mentioned California, Inc. (NASDAQ:PACB). Here is what the fund said:

“As a final word on Sequencing – we established a position in Pacific Biosciences (PACB US) during the quarter. Pac Bio are the leader in Long Read Sequencing (Illumina are dominant in Short Read). The Long Read market is far less developed than short read, but our continued research into the genomic sequencing field increased our confidence in the commercial viability for Long Read Sequencing in the coming years. We will discuss the investment case for Pac Bio in more detail in a future letter.”